Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 2.6 CAD 0.78% Market Closed
Market Cap: 119.5m CAD
Have any thoughts about
Theratechnologies Inc?
Write Note

EV/EBIT
Enterprise Value to EBIT

9
Current
-4.4
Median
4
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
9
=
Enterprise Value
116.1m CAD
/
EBIT
9m USD
All Countries
Close
Market Cap EV/EBIT
CA
Theratechnologies Inc
TSX:TH
119.5m CAD 9
FR
Pharnext SCA
OTC:PNEXF
6T USD -217 582.8
US
Abbvie Inc
NYSE:ABBV
318.1B USD 23.9
US
Amgen Inc
NASDAQ:AMGN
142.2B USD 30.5
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD 22.7
US
Epizyme Inc
F:EPE
94.1B EUR -499.7
AU
CSL Ltd
ASX:CSL
135.7B AUD 24.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 17.1
US
Seagen Inc
F:SGT
39.3B EUR -52.9
NL
argenx SE
XBRU:ARGX
36.2B EUR -79.9
EBIT Growth EV/EBIT to Growth
CA
Theratechnologies Inc
TSX:TH
Average EV/EBIT: 19.7
9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 582.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.9
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.5
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -499.7 N/A N/A
AU
CSL Ltd
ASX:CSL
24.7
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.9 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
6.6
2-Years Forward
EV/EBIT
4.6
3-Years Forward
EV/EBIT
3.5

See Also

Discover More